Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
The purpose of this study is to examine the safety and feasibility of performing
 hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the
 accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with
 infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging

 The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this
 study.

 Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).
Inclusion Criteria:

 -  • Patients with a new brain lesion interpreted as suspected infiltrating gliomas
 including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO
 grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR,
 patients with prior history of infiltrating glioma scheduled for surgery for tumor
 biopsy or resection.

 -  Ages 18-80, including male and female

 -  Suitable to undergo contrast-enhanced MRI

 -  Negative serum pregnancy test

 Exclusion Criteria:

 -  Inability to undergo MRI scan

 -  Inability to receive IV contrast secondary to severe reaction or renal insufficiency.